Adams Diversified Equity Fund Inc. Has $18.20 Million Position in Cencora, Inc. (NYSE:COR)

Adams Diversified Equity Fund Inc. increased its position in Cencora, Inc. (NYSE:COR - Free Report) by 17.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 81,000 shares of the company's stock after purchasing an additional 11,800 shares during the quarter. Adams Diversified Equity Fund Inc.'s holdings in Cencora were worth $18,199,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. JFS Wealth Advisors LLC boosted its position in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after purchasing an additional 46 shares during the last quarter. SBI Securities Co. Ltd. acquired a new position in shares of Cencora during the 4th quarter worth about $30,000. Kentucky Trust Co bought a new stake in shares of Cencora in the 4th quarter valued at about $33,000. Householder Group Estate & Retirement Specialist LLC raised its position in shares of Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after acquiring an additional 69 shares during the period. Finally, WASHINGTON TRUST Co boosted its stake in Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after acquiring an additional 46 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of the company's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the sale, the executive vice president now directly owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. This represents a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the sale, the chief accounting officer now owns 20,154 shares of the company's stock, valued at approximately $5,241,249.24. This represents a 9.03 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,970 shares of company stock worth $2,998,670. Corporate insiders own 10.80% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on COR shares. StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Evercore ISI raised their price objective on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. JPMorgan Chase & Co. lifted their target price on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Wells Fargo & Company increased their price target on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a report on Friday, March 14th. Finally, Mizuho started coverage on Cencora in a report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, Cencora presently has a consensus rating of "Moderate Buy" and a consensus price target of $280.20.

Cencora Stock Up 0.3 %

NYSE COR traded up $0.81 during trading on Tuesday, hitting $268.31. The stock had a trading volume of 1,448,886 shares, compared to its average volume of 1,377,743. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $271.08. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The company's 50-day moving average price is $251.24 and its two-hundred day moving average price is $240.23. The company has a market capitalization of $52.03 billion, a PE ratio of 38.17, a P/E/G ratio of 1.31 and a beta of 0.51.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, sell-side analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.82%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's dividend payout ratio is currently 31.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.